Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Iradimed Corp · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There have been no material changes in our market risks from those disclosed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of the 2025 Annual Report. 24